Schrodinger, Inc. (SDGR) stock
SDGRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3044% above fair value
$25.66−1.70 (-6.21%)
Close on Nov 17, 2026Market cap $1.92BP/E –Yield –
Schrodinger r&d expenses
Research and development expenses are spending on new products and technology.
Schrodinger's R&D Expenses for the twelve months ending Jun 30, 2026 was $168.98M, down 10.7% year over year. For fiscal 2025 it was $173.14M, down 14.2% from the year before. The highest annual figure on record is $201.79M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $173.14M | -14.2% |
| FY2024 | Dec 31, 2024 | $201.79M | +11.0% |
| FY2023 | Dec 31, 2023 | $181.77M | +43.8% |
| FY2022 | Dec 31, 2022 | $126.37M | +39.0% |
| FY2021 | Dec 31, 2021 | $90.90M | +40.5% |
| FY2020 | Dec 31, 2020 | $64.70M | +64.2% |
| FY2019 | Dec 31, 2019 | $39.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $41.00M | -5.0% |
| Q1 FY2026 | Mar 31, 2026 | $43.82M | -4.4% |
| Q4 FY2025 | Dec 31, 2025 | $41.40M | -16.1% |
| Q3 FY2025 | Sep 30, 2025 | $42.76M | -16.1% |
| Q2 FY2025 | Jun 30, 2025 | $43.14M | -15.1% |
| Q1 FY2025 | Mar 31, 2025 | $45.84M | -9.4% |
| Q4 FY2024 | Dec 31, 2024 | $49.36M | -4.1% |
| Q3 FY2024 | Sep 30, 2024 | $50.98M | +8.8% |
| Q2 FY2024 | Jun 30, 2024 | $50.84M | +19.0% |
| Q1 FY2024 | Mar 31, 2024 | $50.61M | +24.2% |
| Q4 FY2023 | Dec 31, 2023 | $51.49M | +49.1% |
| Q3 FY2023 | Sep 30, 2023 | $46.83M | +42.4% |
| Q2 FY2023 | Jun 30, 2023 | $42.71M | +37.2% |
| Q1 FY2023 | Mar 31, 2023 | $40.74M | +46.4% |
| Q4 FY2022 | Dec 31, 2022 | $34.54M | +37.4% |
| Q3 FY2022 | Sep 30, 2022 | $32.89M | +41.6% |
| Q2 FY2022 | Jun 30, 2022 | $31.12M | +47.6% |
| Q1 FY2022 | Mar 31, 2022 | $27.82M | +29.7% |
| Q4 FY2021 | Dec 31, 2021 | $25.15M | +45.2% |
| Q3 FY2021 | Sep 30, 2021 | $23.22M | +36.4% |
| Q2 FY2021 | Jun 30, 2021 | $21.09M | +26.6% |
| Q1 FY2021 | Mar 31, 2021 | $21.45M | +56.6% |
| Q4 FY2020 | Dec 31, 2020 | $17.32M | +56.3% |
| Q3 FY2020 | Sep 30, 2020 | $17.02M | +64.4% |
| Q2 FY2020 | Jun 30, 2020 | $16.66M | +74.8% |
| Q1 FY2020 | Mar 31, 2020 | $13.70M | +62.4% |
| Q4 FY2019 | Dec 31, 2019 | $11.08M | – |
| Q3 FY2019 | Sep 30, 2019 | $10.35M | – |
| Q2 FY2019 | Jun 30, 2019 | $9.53M | – |
| Q1 FY2019 | Mar 31, 2019 | $8.44M | – |
See a number that looks wrong?